Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial

Esmaeilzadeh, Hossein; Nabavi, Mohammad; Aryan, Zahra; Arshi, Saba; Bemanian, Mohammad Hassan; Fallahpour, Morteza; Mortazavi, Negar

doi:10.1016/j.clim.2015.05.012

Cited by 68 publications

(107 citation statements)

References 34 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Patients with a more severe endotype of NP such as eosinophilic NP, or CRSwNP patients who had concomitant respiratory diseases such as bronchial asthma showed higher IL-10 expression levels in their blood or tissue samples, as opposed to patients who suffered a milder endotype of NP such as non-eosinophilc NP, or CRSwNP patients without any concomitant respiratory diseases [13–17,21,22,35,45–49]. Hossein Esmaeilzadeh et al .…”

Section: Discussionmentioning

confidence: 99%

“…The harvested nasal mucosa was immediately soaked in TRIzol @ reagent for subsequent mRNA analysis. Nasal lavage was performed according to the method previously described [35]. Briefly, after partial tracheal resection under deep anesthesia, a micropipette was inserted into the posterior choana through the tracheal opening in the direction of the upper airway.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Role of Interleukin-10 on Nasal Polypogenesis in Patients with Chronic Rhinosinusitis with Nasal Polyps

Xu¹,

Han²,

Kim³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

Background and ObjectivesInterleukin 10 (IL-10) is a potent anti-inflammatory cytokine. The dysregulation of IL-10 is associated with an enhanced immunopathologic response to infection, as well as with an increased risk for developing numerous autoimmune diseases. In this study, we investigated IL-10 expression in chronic rhinosinusitis with nasal polyps (CRSwNP) and assessed the possible role of IL-10 in the pathogenesis of CRSwNP.Materials and MethodsThirty-five patients with CRSwNP, 12 patients with chronic rhinosinusitis without NP (CRSsNP) and 10 control subjects were enrolled in this study. NP tissues and uncinated tissues (UT) were collected for analysis. Dispersed NP cells (DNPCs) were cultured in the presence or absence of IL-25 and IL-10, and a flow cytometric assay was performed to identify the constitutive cell populations of the DNPCs. Murine NP (n = 18) models were used for the in vivo experiments. Real-time PCR, immunohistochemistry, western blotting analysis and ELISA were performed to measure the expression levels of the selected inflammatory cytokines and inflammation-associated molecules.ResultsThe mRNA expression levels of IL-10, IL-5, IL-17A, IL-25 and interferon gamma (IFN-γ) were significantly higher in the NP tissues than in the UT tissues. Strong positive correlations were observed between IL-10 and a variety of inflammatory cytokines (IL-5, IL-17A, IL-25, IFN-γ) and inflammation-associated molecules (B-cell activating factor; BAFF, CD19). Other than the IL-25 to IL-10 ratio, the expression ratios of the other measured inflammatory cytokines to IL-10 were significantly lower in the CRSwNP group than in the CRSsNP or control groups. Administrating IL-25 into the cultured DNPCs significantly increased the production of IL-10, but administrating IL-10 had no effect on the production of IL-25.ConclusionIncreased expression of IL-10, IL-10 related inflammatory cytokine, and IL-10 related B cell activation indicated that IL-10, a potent anti-inflammatory cytokine, has a pivotal role in the pathogenesis of CRSwNPs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Role of Interleukin-10 on Nasal Polypogenesis in Patients with Chronic Rhinosinusitis with Nasal Polyps

Xu¹,

Han²,

Kim³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Many studies have shown that AD followed by daily aspirin treatment was associated with an improved clinical course in patients with AERD [8,[19][20][21][22][23][24][25][26][27][28][29][30][31][32] . A wide of aspirin dosages (100-1,300 mg/day) were used for the purpose of AD in these studies.…”

Section: Clinical Trials Of Admentioning

confidence: 99%

“…A wide of aspirin dosages (100-1,300 mg/day) were used for the purpose of AD in these studies. There was varying degree of clinical benefit obtained from AD in different studies; some showing benefit for only control of upper airway disease [8,[20][21][22] and some for both upper and lower airway disease [19,[23][24][25][26][27][28][29][30][31][32] . To our knowledge, in only one study, which was carried out on 10 aspirin sensitive asthma patients by using 500 mg aspirin, AD was found ineffective as measured as an improvement on pulmonary function tests and reduced need for systemic corticosteroids [33] .…”

Section: Clinical Trials Of Admentioning

confidence: 99%

See 1 more Smart Citation

Aspirin Desensitization Treatment for the Management of Aspirin-Exacerbated Respiratory Disease

Cömert

Karakaya

Kalyoncu

2016

Journal of Respiratory Research

View full text Add to dashboard Cite

Aspirin-exacerbated respiratory disease (AERD) is a clinical syndrome characterized by nasal polyps, chronic hypertrophic eosinophilic sinusitis, asthma, and sensitivity to cyclooxygenase-1 (COX-1) inhibitors. The treatment of asthma and chronic rhinosinusitis in AERD is difficult, since those patients usually suffer from severe steroid dependent asthma and frequent recurrence of nasal polyps despite combined medical and surgical treatment. Aspirin desensitization (AD) can be considered as an additional treatment option in selected patients with AERD. Aspirin doses ranging from 100 to 1,300 mg/day were reported to be effective for this purpose.

show abstract

Use of Nonmedicated Control Substances in Randomized Clinical Trials of Patients With Chronic Rhinosinusitis

Caulley

James

Hopkins

2021

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

IMPORTANCEThe effect of nonmedicated control substances in chronic rhinosinusitis remains unclear.OBJECTIVE To assess the association of nonmedicated control substances in randomized clinical trials with disease outcomes in patients diagnosed with chronic rhinosinusitis. DATA SOURCES AND STUDY SELECTIONIn this single-arm systematic review and meta-analysis, the Cochrane Library of Systematic Reviews, Ovid MEDLINE, Embase, PubMed, and ClinicalTrials.gov databases were searched for randomized clinical trials with a preintervention and postintervention design for chronic rhinosinusitis that were published between 1946 and January 23, 2019.DATA EXTRACTION AND SYNTHESIS Paired reviewers independently extracted data. The analyses used random-effects models and the Cochrane risk of bias assessment to rate the quality of the evidence. MAIN OUTCOMES AND MEASURESThe primary outcomes were the association of nonmedicated control substances with 22-item Sinonasal Outcome Test (SNOT-22) scores or nasal symptom scores when SNOT-22 was not available.RESULTS A total of 2305 abstracts were identified and screened, 725 articles were reviewed in full text, and 38 articles met the study criteria and were included in the meta-analysis. Among the 38 included studies, a total of 2258 adults (mean age range, 27-53 years; 20.0%-72.5% women) were randomized to receive nonmedicated control substances or sham interventions. Topical nonmedicated control substances were associated with significant reduction in SNOT-22 scores (mean difference [MD], −8.81; 95% CI, −12.60 to −5.03). A subgroup analysis of topical therapies, limited to saline irrigation and nasal spray diluents, found that topical diluents were associated with a greater reduction in SNOT-22 scores (MD, −11.45; 95% CI, −13.50 to −9.41) compared with saline irrigation (MD, 95% CI,. Nonmedicated control substances were associated with a significant reduction in nasal obstruction scores (standardized MD [SMD], −0.42; 95% CI, −0.81 to −0.03). No significant change was found in rhinorrhea scores (SMD, −0.34; 95% CI, −1.37 to 0.69), postnasal drip scores (SMD, −0.96; 95% CI, −2.18 to 0.25), facial pain scores (SMD, −0.57; 95% CI, −1.68 to 0.55), or loss of smell scores (SMD, −0.18; 95% CI, −0.68 to 0.32). CONCLUSIONS AND RELEVANCEThis systematic review and meta-analysis of the use of nonmedicated control substances in randomized clinical trials of chronic rhinosinusitis outcomes suggests that the use of nonmedicated control substances is associated with limited improvements in SNOT-22 and nasal obstruction scores. These findings highlight potential areas of future research directions and the importance of randomized clinical trials to accurately estimate treatment effect.

show abstract

Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial

Cited by 68 publications

References 34 publications

Role of Interleukin-10 on Nasal Polypogenesis in Patients with Chronic Rhinosinusitis with Nasal Polyps

Role of Interleukin-10 on Nasal Polypogenesis in Patients with Chronic Rhinosinusitis with Nasal Polyps

Aspirin Desensitization Treatment for the Management of Aspirin-Exacerbated Respiratory Disease

Use of Nonmedicated Control Substances in Randomized Clinical Trials of Patients With Chronic Rhinosinusitis

Contact Info

Product

Resources

About